Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies

Roland E. Schmieder, Rudolph Schutte, Helmut Schumacher, Michael Böhm, Giuseppe Mancia, Michael A. Weber, Matthew McQueen, Koon Teo, Salim Yusuf

Research output: Contribution to journalArticle

Abstract

Aims/hypothesis Urinary albumin excretion is a strong predictor of cardiovascular disease. It is uncertain whether improvement from microalbuminuria or deterioration from normoalbuminuria over time in patients with differing changes in glucose and BP change their cardiovascular risk. Methods Data on mortality, cardiovascular and renal outcomes were analysed in 22,984 patients from two large parallel randomised clinical trials followed for 56 months. A central laboratory analysed first morning spot urine samples at baseline and after 24 months, and events were recorded over the subsequent 32 months. Patients were stratified by changes in albuminuria, glucose status and mean systolic BP over 2 years. Results There was a strong association between albuminuria status and all-cause and cardiovascular mortality and combined cardiovascular and renal endpoints (all p

Original languageEnglish
Pages (from-to)2019-2029
Number of pages11
JournalDiabetologia
Volume57
Issue number10
DOIs
Publication statusPublished - Jul 19 2014

Fingerprint

Albuminuria
Blood Pressure
Morbidity
Glucose
Mortality
Kidney
Albumins
Cardiovascular Diseases
Randomized Controlled Trials
Urine

Keywords

  • Albuminuria
  • Cardiovascular disease
  • Change
  • Prognosis

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure : an analysis of the ONTARGET and TRANSCEND studies. / Schmieder, Roland E.; Schutte, Rudolph; Schumacher, Helmut; Böhm, Michael; Mancia, Giuseppe; Weber, Michael A.; McQueen, Matthew; Teo, Koon; Yusuf, Salim.

In: Diabetologia, Vol. 57, No. 10, 19.07.2014, p. 2019-2029.

Research output: Contribution to journalArticle

Schmieder, RE, Schutte, R, Schumacher, H, Böhm, M, Mancia, G, Weber, MA, McQueen, M, Teo, K & Yusuf, S 2014, 'Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies', Diabetologia, vol. 57, no. 10, pp. 2019-2029. https://doi.org/10.1007/s00125-014-3330-9
Schmieder, Roland E. ; Schutte, Rudolph ; Schumacher, Helmut ; Böhm, Michael ; Mancia, Giuseppe ; Weber, Michael A. ; McQueen, Matthew ; Teo, Koon ; Yusuf, Salim. / Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure : an analysis of the ONTARGET and TRANSCEND studies. In: Diabetologia. 2014 ; Vol. 57, No. 10. pp. 2019-2029.
@article{03bc8fea8fd14c148506eefcf740247e,
title = "Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies",
abstract = "Aims/hypothesis Urinary albumin excretion is a strong predictor of cardiovascular disease. It is uncertain whether improvement from microalbuminuria or deterioration from normoalbuminuria over time in patients with differing changes in glucose and BP change their cardiovascular risk. Methods Data on mortality, cardiovascular and renal outcomes were analysed in 22,984 patients from two large parallel randomised clinical trials followed for 56 months. A central laboratory analysed first morning spot urine samples at baseline and after 24 months, and events were recorded over the subsequent 32 months. Patients were stratified by changes in albuminuria, glucose status and mean systolic BP over 2 years. Results There was a strong association between albuminuria status and all-cause and cardiovascular mortality and combined cardiovascular and renal endpoints (all p",
keywords = "Albuminuria, Cardiovascular disease, Change, Prognosis",
author = "Schmieder, {Roland E.} and Rudolph Schutte and Helmut Schumacher and Michael B{\"o}hm and Giuseppe Mancia and Weber, {Michael A.} and Matthew McQueen and Koon Teo and Salim Yusuf",
year = "2014",
month = "7",
day = "19",
doi = "10.1007/s00125-014-3330-9",
language = "English",
volume = "57",
pages = "2019--2029",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure

T2 - an analysis of the ONTARGET and TRANSCEND studies

AU - Schmieder, Roland E.

AU - Schutte, Rudolph

AU - Schumacher, Helmut

AU - Böhm, Michael

AU - Mancia, Giuseppe

AU - Weber, Michael A.

AU - McQueen, Matthew

AU - Teo, Koon

AU - Yusuf, Salim

PY - 2014/7/19

Y1 - 2014/7/19

N2 - Aims/hypothesis Urinary albumin excretion is a strong predictor of cardiovascular disease. It is uncertain whether improvement from microalbuminuria or deterioration from normoalbuminuria over time in patients with differing changes in glucose and BP change their cardiovascular risk. Methods Data on mortality, cardiovascular and renal outcomes were analysed in 22,984 patients from two large parallel randomised clinical trials followed for 56 months. A central laboratory analysed first morning spot urine samples at baseline and after 24 months, and events were recorded over the subsequent 32 months. Patients were stratified by changes in albuminuria, glucose status and mean systolic BP over 2 years. Results There was a strong association between albuminuria status and all-cause and cardiovascular mortality and combined cardiovascular and renal endpoints (all p

AB - Aims/hypothesis Urinary albumin excretion is a strong predictor of cardiovascular disease. It is uncertain whether improvement from microalbuminuria or deterioration from normoalbuminuria over time in patients with differing changes in glucose and BP change their cardiovascular risk. Methods Data on mortality, cardiovascular and renal outcomes were analysed in 22,984 patients from two large parallel randomised clinical trials followed for 56 months. A central laboratory analysed first morning spot urine samples at baseline and after 24 months, and events were recorded over the subsequent 32 months. Patients were stratified by changes in albuminuria, glucose status and mean systolic BP over 2 years. Results There was a strong association between albuminuria status and all-cause and cardiovascular mortality and combined cardiovascular and renal endpoints (all p

KW - Albuminuria

KW - Cardiovascular disease

KW - Change

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84926610786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926610786&partnerID=8YFLogxK

U2 - 10.1007/s00125-014-3330-9

DO - 10.1007/s00125-014-3330-9

M3 - Article

C2 - 25037746

AN - SCOPUS:84926610786

VL - 57

SP - 2019

EP - 2029

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 10

ER -